CASI Pharmaceuticals, Inc (DE) (CASI) [Rocket]

Overview

CASI Pharmaceuticals, Inc (DE) (CASI)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
04/26/2023	20-F	Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
03/27/2023	EFFECT	Form EFFECT - Notice of Effectiveness:
03/22/2023	15-12G	Form 15-12G - Securities registration termination [Section 12(g)]:
03/21/2023	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/21/2023	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/21/2023	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/21/2023	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14
Revenues	30.2	15.1	4.1	0.0	0.0	0.0	0.0	0.0
Revenue growth	99.2%	266.5%				-100.0%	101.1%
Cost of goods sold	19.2	16.1	3.9	0.0	0.0	0.0	0.0	0.0
Gross profit	11.0	-0.9	0.2	0.0	0.0	0.0	0.0	0.0
Gross margin	36.4%	-6.1%	4.7%				86.9%	68.5%
Sales and marketing	14.7	7.8	3.1
Research and development	14.4	11.5	9.3	8.5	7.6	4.6	4.1	2.8
General and administrative	23.8	19.7	27.3	18.0	3.2	4.8	3.1	3.8
EBITA	-33.9	-32.0	-38.0	-25.2	-10.8	-9.5	-7.1	-6.5
EBITA margin	-112.5%	-211.5%	-920.7%				-14933.1%	-27369.7%
Amortization of intangibles	1.3	1.3	1.6	1.3
EBIT	-35.3	-33.3	-39.6	-26.5	-10.8	-9.5	-7.1	-6.5
EBIT margin	-117.0%	-220.0%	-958.2%				-14933.1%	-27369.7%
Pre-tax income	-35.8	-47.5	-45.4	-27.5	-10.8	-9.5	-7.2	-26.2
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-35.8	-47.5	-45.4	-27.5	-10.8	-9.5	-7.2	-26.2
Net margin	-118.8%	-313.8%	-1098.1%				-15104.0%	-110432.5%

Diluted EPS	($0.26)	($0.43)	($0.47)	($0.32)	($0.18)	($0.17)	($0.22)	($0.92)
Shares outstanding (diluted)	136.1	110.5	95.9	84.8	61.5	55.9	32.4	28.6

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.